Table 2

Proportion of cancers that show PD-L1 expression on the malignant cells11

Cancer typeProportion showing PD-L1 expression
Non-small cell carcinoma20%–30% (show expression in >50% cells)
Malignant melanoma24%–49%
Ovarian carcinoma70%
Breast carcinoma20% (of ‘triple negative’ tumours)
Colorectal carcinoma5% (associated with MMR deficiency)
Pancreatic carcinomaRare
Head and neck carcinoma15%–20%
Urothelial carcinoma4% (but higher in TILs)
B cell lymphomas and Hodgkin’s diseaseCommon
  • MMR, DNA mismatch repair enzyme;PD-L1, programmed death-ligand 1; TILs, tumour-infiltrating lymphocytes; triple negative, oestrogen receptor, progesterone receptor and HER-2 negative.